Literature DB >> 8263775

Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo.

D Raeburn1, J A Karlsson.   

Abstract

The effects of drugs elevating cyclic nucleotide concentrations or inhibiting cyclic nucleotide phosphodiesterase (PDE) activity on platelet activating factor (PAF)-induced microvascular leak (MVL) was examined in the anesthetized guinea pig. Drugs were dosed as dry powders directly into the tracheobronchial tree and MVL was assessed by using the fluorescent macromolecule fluorescein isothiocyanate-dextran (FITC-dextran, 150 kD). Basal FITC-dextran content was 15 +/- 1 and 23 +/- 4 ng.mg-1 of tracheal and bronchial tissue, respectively, and 0.6 +/- 0.03 micrograms.ml-1 of tracheobronchial lavage fluid. PAF (2-8 nmol, intratracheal (i.t.) administration) produced a dose-dependent increase in MVL; the maximum increase being 100% in tracheal and bronchial tissue and 400% in lavage fluid. PAF (16 nmol) produced acute bronchospasm. The beta-2 adrenoceptor agonist salbutamol (50 or 200 micrograms i.t.) and the nitrovasodilator sodium nitroprusside (200 or 500 micrograms i.t.), which activate adenylyl and guanylyl cyclases, respectively, potently and significantly (P < .05) inhibited PAF-induced MVL in airway tissues and in the airway lumen by 60 to 100%. Sodium nitroprusside (50 micrograms i.t.) only significantly inhibited MVL into the lavage fluid. Inhibition of PDE type IV with rolipram (200 micrograms i.t.) or PDE type V with zaprinast (200 micrograms i.t.) potently (by 70-100%) and significantly (P < .05) reduced MVL into the airways. Lower doses (20 micrograms) were without effect. Neither vinpocetine (PDE type I inhibitor) nor siguazodan (PDE type III inhibitor) inhibited MVL. Theophylline (200 micrograms i.t.) inhibited MVL into lower airway tissues and lavage fluid but was without marked effect in tracheal tissues.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263775

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

Authors:  J L Ortiz; J M Vallés; M Martí-Cabrera; J Cortijo; E J Morcillo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

4.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

5.  Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.

Authors:  W Elwood; J Sun; P J Barnes; M A Giembycz; K F Chung
Journal:  Inflamm Res       Date:  1995-02       Impact factor: 4.575

6.  Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.

Authors:  D Raeburn; S L Underwood; S A Lewis; V R Woodman; C H Battram; A Tomkinson; S Sharma; R Jordan; J E Souness; S E Webber
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

7.  Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice.

Authors:  Yuri A Blednov; Jillian M Benavidez; Mendy Black; R Adron Harris
Journal:  Front Neurosci       Date:  2014-05-27       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.